Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on COVID-19 Prevention Using Sipavibart and Cilgavimab for Patients with Weakened Immune Systems

Fast replyRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the prevention of COVID-19, a disease caused by the SARS-CoV-2 virus, in people with weakened immune systems. The study will test a new treatment called Sipavibart (also known by its code name AZD3152), which is a type of protein designed to help the body fight off the virus. Another treatment being studied is EVUSHELD, which contains a protein called cilgavimab. Both treatments are given as injections. The study will also use a substance called sodium chloride as a comparison.

The purpose of the study is to evaluate the safety and effectiveness of these treatments in preventing symptoms of COVID-19. Participants will receive either Sipavibart, EVUSHELD, or a placebo. The study will monitor participants over a period of time to see if they develop symptoms of COVID-19 and to assess any side effects from the treatments. The study will also look at how well the treatments work against different variants of the virus.

Participants in the study will be monitored for any side effects and the occurrence of COVID-19 symptoms. The study will also measure the levels of the treatments in the body over time. This research aims to provide valuable information on how these treatments can help protect people with immune system challenges from COVID-19.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial visit

    Upon joining the study, you will attend an initial visit. During this visit, a rapid antigen test will be conducted to ensure you are negative for COVID-19. This is a necessary step before receiving any study medication.

    You will be asked to provide written informed consent, confirming your understanding of the study and your willingness to participate. If you are between 12 and 18 years old, your parent or legal guardian will also need to provide consent, and you will sign an assent form.

  2. Step 2

    Medication administration

    You will receive an injection of the study medication. The medication options include AZD3152, EVUSHELD, or a placebo. The injection is given intramuscularly, which means it is administered into a muscle.

    The dosage for EVUSHELD is 150 mg of each component, cilgavimab, and tixagevimab, in a solution for injection. The frequency and duration of administration will be determined by the study protocol.

  3. Step 3

    Monitoring and follow-up

    After receiving the medication, you will be monitored for any side effects or adverse events. This monitoring will continue for approximately 90 days after each administration of the study medication.

    You will have follow-up visits to assess your health and the effectiveness of the medication in preventing symptomatic COVID-19. These visits will include evaluations of any symptoms you may experience and additional tests as required by the study.

  4. Step 4

    Completion of study participation

    Your participation in the study will continue until the study's estimated end date, which is February 7, 2025, unless you choose to withdraw earlier.

    At the end of your participation, you will have a final visit to review your health status and any outcomes related to the study.

Who can join the trial?

20 criteria

  • Sentinel Safety Cohort: Must be healthy based on medical history, physical exam, and lab tests, with no other diseases or medications unless allowed by the study.
  • Main Cohort: Must weigh at least 40 kg (about 88 pounds) at screening.
  • Main Cohort: Must have at least one of the following risk factors:
    • Have solid tumor cancer and be on active treatment that weakens the immune system.
    • Have blood cancer.
    • Have had a solid organ transplant or stem cell transplant within the last 2 years, or have chronic graft-versus-host disease.
    • Be taking medicines that weaken the immune system, such as certain steroids or cancer treatments.
    • Have received CAR T cell therapy, a type of treatment that uses modified immune cells.
    • Have received B-cell depleting therapies within the last year, which are treatments that reduce certain immune cells.
    • Have a moderate or severe immune deficiency, either from birth or due to another condition like dialysis.
    • Have advanced or untreated HIV infection with low CD4 cell counts or symptoms.
    • Main Cohort: Must be medically stable, meaning no major changes in treatment or hospital visits for worsening conditions in the last month, and no expected changes at the time of joining the study.
    • Main Cohort: Must be able to understand and follow all study requirements, with help if needed, as assessed by the study doctor.
    • Sentinel Safety Cohort: Must be between 18 and 55 years old at the time of signing the consent form.
    • Sentinel Safety Cohort: Must provide written consent and any required local authorization before any study procedures.
    • Sentinel Safety Cohort: Must have a negative rapid antigen test at the first visit.
    • Sentinel Safety Cohort: Must weigh between 45 kg (about 99 pounds) and 110 kg (about 243 pounds) at screening.
    • Sentinel Safety Cohort: Must be able to understand and follow all study requirements, with help if needed, as assessed by the study doctor.
    • Main Cohort: Must be 12 years or older at the time of signing the consent form.
    • Main Cohort: Must provide written consent and any required local authorization before any study procedures. For those aged 12 to under 18, a parent or guardian must also give consent, and the participant will sign an assent form.
    • Main Cohort: Must have a negative rapid antigen test before receiving the study treatment at the first visit.

Who cannot join the trial?

8 criteria

  • Patients who are currently infected with COVID-19 cannot participate.
  • Patients who have had a severe allergic reaction to similar medications in the past are not eligible.
  • Patients with a history of severe heart problems are excluded.
  • Patients who are pregnant or breastfeeding cannot take part in the study.
  • Patients who are participating in another clinical trial at the same time are not allowed.
  • Patients with a weakened immune system, which means their body has trouble fighting infections, are excluded.
  • Patients who have received a COVID-19 vaccine within the last 30 days are not eligible.
  • Patients with any other medical condition that the study doctors think would make it unsafe for them to participate are excluded.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • AZD3152

    is a medication being studied to see if it can help prevent COVID-19 in people who have weakened immune systems. This medication is being tested to understand how well it can stop the virus from causing symptoms, especially in people who might not respond well to vaccines.

  • EVUSHELD

    is a combination of two antibodies that are designed to help prevent COVID-19 infection. It works by giving your body extra help to fight off the virus, especially if your immune system is not strong enough to do it on its own. This medication is being compared to others to see how effective it is in preventing COVID-19 symptoms.

  • AZD5156

    is another medication being tested in this study. It is being evaluated for its safety and how well it can prevent COVID-19 in people with immune system challenges. The goal is to see if it can be a safe option for protecting against the virus in those who are more vulnerable.

What is already known about the treatment

  • AZD3152

    AZD3152 is administered as an injection and is currently being studied in clinical trials for its potential to prevent COVID-19 in people with weakened immune systems. It is being compared to another medication, EVUSHELD, and a placebo to assess its safety and effectiveness. The main goal is to see how well it can prevent COVID-19 symptoms caused by different variants of the virus. AZD3152 works by targeting the virus at a molecular level to stop it from infecting cells, and it is classified as an antiviral medication.

  • EVUSHELD

    EVUSHELD is given as an injection and is used to prevent COVID-19, especially in individuals with compromised immune systems. It is part of ongoing research to compare its safety and effectiveness against a new medication, AZD3152, and a placebo. EVUSHELD aims to prevent COVID-19 symptoms by neutralizing the virus before it can cause an infection. It belongs to a class of drugs known as monoclonal antibodies, which are designed to mimic the immune system's ability to fight off harmful pathogens.

Investigated diseases

COVID-19 – COVID-19 is an infectious disease caused by the coronavirus SARS-CoV-2. It primarily affects the respiratory system, leading to symptoms such as fever, cough, and difficulty breathing. The disease can progress to more severe respiratory issues, including pneumonia and acute respiratory distress syndrome. COVID-19 spreads through respiratory droplets when an infected person coughs, sneezes, or talks. The virus can also spread by touching surfaces contaminated with the virus and then touching the face. The progression and severity of the disease can vary widely among individuals.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-512554-15-00Protocol codeD7000C00001Estimated enrolment3 349 patientsSponsorAstraZeneca AB

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.